Novo and Orsted Made Denmark Rich. Are The Boom Times Now Over?

Danish corporate champions Novo Nordisk and Orsted, once highly valued, are now facing significant reversals. Novo Nordisk, which became Europe's most valuable company on demand for Ozempic/Wegovy, announced 9,000 job cuts and lost its US obesity market lead to Eli Lilly. Concurrently, offshore wind developer Orsted has scrapped multi-billion dollar projects, taken substantial write-downs, and raised capital due to soaring costs, supply chain disruptions, and political opposition. These developments have resulted in steep valuation losses and diminished investor confidence, signaling a potential end to their period of rapid growth.

Analysis

Two of Denmark's corporate champions, Novo Nordisk (NVO) and Orsted A/S, are experiencing significant operational and financial reversals, casting doubt on their recent high-growth trajectories. Novo Nordisk, previously Europe's most valuable company due to strong demand for its obesity drugs Ozempic and Wegovy, has announced 9,000 job cuts after losing its leadership position in the U.S. obesity market to rival Eli Lilly & Co. (LLY). This signals intensifying competitive pressure that has eroded its market dominance. Simultaneously, Orsted, the world's largest offshore wind developer, is facing a confluence of negative factors including soaring costs, supply-chain disruptions, and adverse political developments. These challenges have forced the company to scrap multibillion-dollar projects, recognize substantial write-downs, and seek new capital. The combined effect for both firms has been a steep decline in valuation and a pronounced evaporation of the investor euphoria that characterized their peak performance.

Key Decisions for Investors

• Investors in Novo Nordisk should closely monitor its competitive positioning against Eli Lilly in the crucial U.S. obesity market, as the recent job cuts and loss of market leadership signal a significant threat to its growth outlook.
• Holders of Orsted should re-evaluate the company's risk profile given the material impact of rising costs, supply chain issues, and political headwinds, which have already led to project cancellations and substantial write-downs.
• The concurrent struggles of these two major Danish companies suggest a potential increase in country-specific risk, warranting a review of concentrated exposure to the Danish market.